Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...
Detailed price information for Roche Holding Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
Merck MRK announced that the FDA has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and its subcutaneous ...
The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...
The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...
Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in ...
FDA expanded perioperative pembrolizumab plus enfortumab vedotin to resectable MIBC regardless of cisplatin eligibility, administered pre-cystectomy/PLND with continued postoperative therapy.
Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.
The Food and Drug Administration approved a combination treatment by Merck & Co., Pfizer, and Astellas Pharma for a hard-to-treat form of bladder cancer. The agency greenlit Merck's Keytruda and its ...
Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results